NCT05611229View on ClinicalTrials.gov

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

CompletedOBSERVATIONAL
Enrollment

1,975

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

December 3, 2021

Study Completion Date

December 3, 2021

Conditions
Metastatic Melanoma
Interventions
DRUG

Nivolumab

Nivolumab

DRUG

Pembrolizumab

Pembrolizumab

COMBINATION_PRODUCT

Dabrafenib+Trametinib

Dabrafenib+Trametinib

COMBINATION_PRODUCT

Ipilimumab+Nivolumab

Ipilimumab+Nivolumab

COMBINATION_PRODUCT

Vemurafenib+Cobimetinib

Vemurafenib+Cobimetinib

COMBINATION_PRODUCT

Encorafenib+Binimetinib

Encorafenib+Binimetinib

Trial Locations (1)

07936

Novartis Investigative Site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY